뮤코다당증(MPS) 치료 시장 : 규모, 점유율, 성장, 산업 분석, 유형별, 용도별, 지역별 인사이트, 예측(2026-2034년)

Growth Factors of mucopolysaccharidosis (MPS) treatment Market

The global mucopolysaccharidosis (MPS) treatment market is projected to witness significant growth over the coming decade. In 2025, the market was valued at USD 3.96 billion, expected to grow to USD 4.37 billion in 2026 and reach USD 9.74 billion by 2034, reflecting a CAGR of 10.54% from 2026-2034. North America dominated the market with a 52.10% share in 2025, primarily driven by high diagnosis rates, strong clinical trial activity, and favorable reimbursement policies.

MPS is a group of rare metabolic disorders caused by deficiencies in lysosomal enzymes, leading to abnormal accumulation of glycosaminoglycans (GAGs) in cells. This results in severe symptoms, including neurological complications, organ dysfunction, and growth abnormalities. The growing need for advanced therapeutics and unmet clinical needs has propelled market growth globally.

Market Drivers

The MPS treatment market is primarily driven by the need for advanced therapeutics due to unmet clinical needs and better treatment outcomes. Current treatments, such as enzyme replacement therapies (ERTs) like Elaprase for Hunter syndrome and Vimizim (elosulfase alfa) for Morquio syndrome, are often prohibitively expensive, limiting access in developing countries. Additionally, existing therapies cannot cross the blood-brain barrier, leaving neurological symptoms largely untreated.

Increasing R&D initiatives by biopharmaceutical companies like ArmaGen, REGENXBIO, and Denali Therapeutics are focusing on developing advanced therapies, including gene therapies and hematopoietic stem cell transplantation (HSCT), to address the full spectrum of MPS symptoms. This pipeline expansion is expected to drive market growth during the forecast period.

Market Restraints

The market faces restraints due to high therapeutic costs, poor diagnosis rates, and limited access in emerging countries. ERTs are extremely expensive, with annual treatment costs reaching six figures, making them unaffordable for many patients. Diagnostic delays, lack of awareness, and insufficient government reimbursement further restrict market expansion in developing regions.

Market Trends

A key trend is the increasing focus on rare and orphan disease therapies. MPS, as an orphan disorder, attracts significant attention from biopharmaceutical companies aiming to develop blockbuster treatments in niche markets. Clinical trials for multiple MPS types are increasing, reflecting growing investment in rare disease drug development.

Additionally, advancements in gene therapy and stem cell treatments represent a shift from conventional ERTs toward potentially curative therapies, increasing the attractiveness of the market to investors and healthcare providers.

Segmentation Analysis

By Treatment Type:

• Enzyme Replacement Therapy (ERT) dominates the market, accounting for 93.89% of the market in 2026, due to its established efficacy in treating lysosomal storage disorders.
• Other treatments, including gene therapy and HSCT, are expected to grow at higher CAGR during the forecast period as more pipeline candidates advance through clinical trials.

By Disease Type:

• MPS II (Hunter Syndrome) is projected to dominate with 24.25% market share in 2026, owing to key products like Elaprase and Hunterase.
• Other types, including MPS I, IV A, VI, and VII (Sly syndrome), are expected to grow steadily, supported by newly approved therapeutics such as MEPSEVII (vestronidase alfa-vjbk).

By Route of Administration:

• Intravenous (IV) administration dominates with 98.16% of revenue in 2026, as most approved therapies, including Elaprase, are delivered intravenously.
• Intracerebroventricular (ICV) administration is limited but gaining attention with products like Hunterase.

By End-User:

• Hospitals dominate the segment with 61.55% share in 2026, given the need for trained professionals to administer IV therapies safely.
• Specialty clinics and other facilities are expanding in developed regions, driven by patient demand for specialized care.

Regional Analysis

North America: Market size of USD 2.06 billion in 2025, projected to reach USD 2.13 billion in 2026, driven by high awareness, reimbursement, and clinical trials.

Europe: Second-largest market with strong product presence; projected to grow at CAGR of 9.9%, with UK reaching USD 0.18 billion and Germany USD 0.27 billion by 2026.

Asia-Pacific: Expected fastest growth due to strong patient base and upcoming therapeutic launches; Japan market USD 333.9 million in 2025, projected to reach USD 0.37 billion in 2026, China market expected to reach USD 0.27 billion, and India USD 0.13 billion by 2026.

Rest of World: Latin America and Middle East & Africa are emerging markets, supported by growing healthcare infrastructure and government initiatives.

Competitive Landscape

The MPS treatment market is semi-consolidated, led by Shire (Takeda Pharmaceutical Company Limited) with Elaprase, and BioMarin with ALDURAZYME, VIMIZIM, and NAGLAZYME. Clinical-stage players like ArmaGen, REGENXBIO, Sangamo Therapeutics, and Denali Therapeutics are developing pipeline candidates to capture future market share. Key developments include FDA Fast Track designations for gene therapy candidates like LYS-SAF302 (Lysogene) and ABO-101 (Abeona Therapeutics).

Conclusion

The global mucopolysaccharidosis treatment market is projected to grow from USD 3.96 billion in 2025 to USD 9.74 billion by 2034, at a CAGR of 10.54%. Market growth is primarily driven by the unmet need for advanced therapeutics, increasing R&D investment in rare disease therapies, and emerging innovative treatments including gene therapy and stem cell interventions. While high costs and limited access in emerging countries remain challenges, expanding clinical pipelines, technological advancements, and increasing awareness are set to fuel sustainable growth in the MPS treatment market across all regions.

Segmentation By Treatment

• Enzyme Replacement Therapy (ERT)
• Others

By Disease Type

• Mucopolysaccharidosis Type I
• Mucopolysaccharidosis Type II
• Mucopolysaccharidosis Type IV A
• Mucopolysaccharidosis Type VI
• Others

By Route of Administration

• Intravenous
• Intracerebroventricular (ICV)

By End User

• Hospitals
• Specialty Clinics
• Others

By Geography

• North America (U.S. and Canada)
• Europe (U.K., Germany, France, Italy, Spain, and Rest of Europe)
• Asia-Pacific (Japan, China, India, South Korea, and Rest of Asia-Pacific)
• Rest of the World

Table of Content

1. Introduction

• 1.1. Research Scope
• 1.2. Market Segmentation
• 1.3. Research Methodology
• 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities

4. Key Insights

• 4.1. Prevalence of Key Mucopolysaccharidosis Types - by key regions (2025)
• 4.2. Pipeline Analysis
• 4.3. Key Industry Developments
• 4.4. Regulatory Scenario- by Key Regions
• 4.5. Overview of Emerging Treatments for Mucopolysaccharidosis
• 4.6. Reimbursement Scenario - by Key Regions

5. Global Mucopolysaccharidosis Treatment Market Analysis, Insights and Forecast, 2021-2034

• 5.1. Key Findings / Summary
• 5.2. Market Analysis, Insights and Forecast - By Treatment
  • 5.2.1. Enzyme Replacement Therapy (ERT)
  • 5.2.2. Others
• 5.3. Market Analysis, Insights and Forecast - By Disease Type
  • 5.3.1. Mucopolysaccharidosis Type I
  • 5.3.2. Mucopolysaccharidosis Type II
  • 5.3.3. Mucopolysaccharidosis Type IV A
  • 5.3.4. Mucopolysaccharidosis Type VI
  • 5.3.5. Others
• 5.4. Market Analysis, Insights and Forecast - By Route of Administration
  • 5.4.1. Intravenous
  • 5.4.2. Intracerebroventricular (ICV)
• 5.5. Market Analysis, Insights and Forecast - By End User
  • 5.5.1. Hospitals
  • 5.5.2. Specialty Clinics
  • 5.5.3. Others
• 5.6. Market Analysis, Insights and Forecast - By Region
  • 5.6.1. North America
  • 5.6.2. Europe
  • 5.6.3. Asia pacific
  • 5.6.4. Rest of the World

6. North America Mucopolysaccharidosis Treatment Market Analysis, Insights and Forecast, 2021-2034

• 6.1. Key Findings / Summary
• 6.2. Market Analysis - By Treatment
  • 6.2.1. Enzyme Replacement Therapy (ERT)
  • 6.2.2. Others
• 6.3. Market Analysis - By Disease Type
  • 6.3.1. Mucopolysaccharidosis Type I
  • 6.3.2. Mucopolysaccharidosis Type II
  • 6.3.3. Mucopolysaccharidosis Type IV A
  • 6.3.4. Mucopolysaccharidosis Type VI
  • 6.3.5. Others
• 6.4. Market Analysis - By Route of Administration
  • 6.4.1. Intravenous
  • 6.4.2. Intracerebroventricular (ICV)
• 6.5. Market Analysis - By End User
  • 6.5.1. Hospitals
  • 6.5.2. Specialty Clinics
  • 6.5.3. Others
• 6.6. Market Analysis - By Country
  • 6.6.1. U.S.
  • 6.6.2. Canada

7. Europe Mucopolysaccharidosis Treatment Market Analysis, Insights and Forecast, 2021-2034

• 7.1. Key Findings / Summary
• 7.2. Market Analysis - By Treatment
  • 7.2.1. Enzyme Replacement Therapy (ERT)
  • 7.2.2. Others
• 7.3. Market Analysis - By Disease Type
  • 7.3.1. Mucopolysaccharidosis Type I
  • 7.3.2. Mucopolysaccharidosis Type II
  • 7.3.3. Mucopolysaccharidosis Type IV A
  • 7.3.4. Mucopolysaccharidosis Type VI
  • 7.3.5. Others
• 7.4. Market Analysis - By Route of Administration
  • 7.4.1. Intravenous
  • 7.4.2. Intracerebroventricular (ICV)
• 7.5. Market Analysis - By End User
  • 7.5.1. Hospitals
  • 7.5.2. Specialty Clinics
  • 7.5.3. Others
• 7.6. Market Analysis - By Country/ sub-region
  • 7.6.1. U.K.
  • 7.6.2. Germany
  • 7.6.3. France
  • 7.6.4. Spain
  • 7.6.5. Italy
  • 7.6.6. Rest of Europe

8. Asia Pacific Mucopolysaccharidosis Treatment Market Analysis, Insights and Forecast, 2021-2034

• 8.1. Key Findings / Summary
• 8.2. Market Analysis - By Treatment
  • 8.2.1. Enzyme Replacement Therapy (ERT)
  • 8.2.2. Others
• 8.3. Market Analysis - By Disease Type
  • 8.3.1. Mucopolysaccharidosis Type I
  • 8.3.2. Mucopolysaccharidosis Type II
  • 8.3.3. Mucopolysaccharidosis Type IV A
  • 8.3.4. Mucopolysaccharidosis Type VI
  • 8.3.5. Others
• 8.4. Market Analysis - By Route of Administration
  • 8.4.1. Intravenous
  • 8.4.2. Intracerebroventricular (ICV)
• 8.5. Market Analysis - By End User
  • 8.5.1. Hospitals
  • 8.5.2. Specialty Clinics
  • 8.5.3. Others
• 8.6. Market Analysis - By Country/ sub-region
  • 8.6.1. Japan
  • 8.6.2. China
  • 8.6.3. India
  • 8.6.4. South Korea
  • 8.6.5. Rest of Asia Pacific

9. Rest of the World Mucopolysaccharidosis Treatment Market Analysis, Insights and Forecast, 2021-2034

• 9.1. Key Findings / Summary
• 9.2. Market Analysis - By Treatment
  • 9.2.1. Enzyme Replacement Therapy (ERT)
  • 9.2.2. Others
• 9.3. Market Analysis - By Disease Type
  • 9.3.1. Mucopolysaccharidosis Type I
  • 9.3.2. Mucopolysaccharidosis Type II
  • 9.3.3. Mucopolysaccharidosis Type IV A
  • 9.3.4. Mucopolysaccharidosis Type VI
  • 9.3.5. Others
• 9.4. Market Analysis - By Route of Administration
  • 9.4.1. Intravenous
  • 9.4.2. Intracerebroventricular (ICV)
• 9.5. Market Analysis - By End User
  • 9.5.1. Hospitals
  • 9.5.2. Specialty Clinics
  • 9.5.3. Others

10. Competitive Analysis

• 10.1. Key Industry Developments
• 10.2. Global Market Share Analysis (2017)
• 10.3. Competition Dashboard
• 10.4. Comparative Analysis - Major Players
• 10.5. Company Profiles (Overview, Products & services, SWOT analysis, Recent developments, strategies, financials (based on availability))
  • 10.5.1. Shire (Takeda Pharmaceutical Company Limited)
    • 10.5.1.1. Overview,
    • 10.5.1.2. Products & services,
    • 10.5.1.3. SWOT analysis,
    • 10.5.1.4. Recent developments,
    • 10.5.1.5. strategies,
    • 10.5.1.6. financials (based on availability)
  • 10.5.2. Denali Therapeutics
    • 10.5.2.1. Overview,
    • 10.5.2.2. Products & services,
    • 10.5.2.3. SWOT analysis,
    • 10.5.2.4. Recent developments,
    • 10.5.2.5. strategies,
    • 10.5.2.6. financials (based on availability)
  • 10.5.3. ArmaGen
    • 10.5.3.1. Overview,
    • 10.5.3.2. Products & services,
    • 10.5.3.3. SWOT analysis,
    • 10.5.3.4. Recent developments,
    • 10.5.3.5. strategies,
    • 10.5.3.6. financials (based on availability)
  • 10.5.4. REGENXBIO Inc.
    • 10.5.4.1. Overview,
    • 10.5.4.2. Products & services,
    • 10.5.4.3. SWOT analysis,
    • 10.5.4.4. Recent developments,
    • 10.5.4.5. strategies,
    • 10.5.4.6. financials (based on availability)
  • 10.5.5. Sangamo Therapeutics
    • 10.5.5.1. Overview,
    • 10.5.5.2. Products & services,
    • 10.5.5.3. SWOT analysis,
    • 10.5.5.4. Recent developments,
    • 10.5.5.5. strategies,
    • 10.5.5.6. financials (based on availability)
  • 10.5.6. BioMarin
    • 10.5.6.1. Overview,
    • 10.5.6.2. Products & services,
    • 10.5.6.3. SWOT analysis,
    • 10.5.6.4. Recent developments,
    • 10.5.6.5. strategies,
    • 10.5.6.6. financials (based on availability)
  • 10.5.7. Lysogene
    • 10.5.7.1. Overview,
    • 10.5.7.2. Products & services,
    • 10.5.7.3. SWOT analysis,
    • 10.5.7.4. Recent developments,
    • 10.5.7.5. strategies,
    • 10.5.7.6. financials (based on availability)
  • 10.5.8. Abeona Therapeutics Inc.
    • 10.5.8.1. Overview,
    • 10.5.8.2. Products & services,
    • 10.5.8.3. SWOT analysis,
    • 10.5.8.4. Recent developments,
    • 10.5.8.5. strategies,
    • 10.5.8.6. financials (based on availability)
  • 10.5.9. Ultragenyx Pharmaceutical
    • 10.5.9.1. Overview,
    • 10.5.9.2. Products & services,
    • 10.5.9.3. SWOT analysis,
    • 10.5.9.4. Recent developments,
    • 10.5.9.5. strategies,
    • 10.5.9.6. financials (based on availability)
  • 10.5.10. Genzyme Corporation
    • 10.5.10.1. Overview,
    • 10.5.10.2. Products & services,
    • 10.5.10.3. SWOT analysis,
    • 10.5.10.4. Recent developments,
    • 10.5.10.5. strategies,
    • 10.5.10.6. financials (based on availability)

11. Competitive Analysis